You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,057,792

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,057,792

Title:	Use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposus
Abstract:	The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
Inventor(s):	Olmarker; Kjell (Molndal, SE), Rydevik; Bjorn (Goteborg, SE)
Assignee:	Sciaticon AB (Molndal, SE)
Application Number:	12/714,708
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,057,792
Patent Claims:	1. A method of treating or alleviating one or more symptoms of a nerve disorder mediated by nucleus pulposus in a mammal comprising administering to the mammal a therapeutically effective amount of an antibody that blocks TNF-.alpha. activity, wherein the antibody is selected from the group consisting of murine monoclonal antibodies, chimeric antibodies, humanized antibodies and human monoclonal antibodies. 2. The method of claim 1, wherein the antibody that blocks TNF-.alpha. activity is a complete or intact antibody. 3. The method of claim 1, wherein the antibody that blocks TNF-.alpha. activity is selected from the group consisting of infliximab, CDP-571, D2E7 and CDP-870. 4. The method of claim 1, wherein the antibody that blocks TNF-.alpha. activity comprises an immunogenic fragment of an antibody which binds to an epitope of TNF-.alpha.. 5. The method of claim 4, wherein the immunogenic fragment is selected from the group consisting of Fab fragments, scFv, and F(ab)2 fragments. 6. The method of claim 1, wherein the antibody is administered systemically. 7. The method of claim 1, wherein the antibody is administered orally. 8. The method of claim 1, wherein the antibody is administered intramuscularly. 9. The method of claim 1, wherein the antibody is administered intravenously. 10. The method of claim 1, wherein the antibody is administered locally. 11. The method of claim 1, wherein the antibody is administered epidurally. 12. The method of claim 1, wherein the nerve disorder involves pain. 13. The method of claim 1, wherein the nerve disorder is a nerve root injury. 14. The method of claim 1, wherein the nerve disorder presents as sciatica. 15. The method of claim 1, wherein the nerve disorder is caused by a herniated disc. 16. A method of treating or alleviating one or more symptoms of a herniated disc in a mammal comprising administering to the mammal a therapeutically effective amount of an antibody that blocks TNF-.alpha. activity, wherein the antibody is selected from the group consisting of murine monoclonal antibodies, chimeric antibodies, humanized antibodies and human monoclonal antibodies. 17. The method of claim 16, wherein the antibody that blocks TNF-.alpha. activity is a complete or intact antibody. 18. A method of treating or alleviating one or more symptoms of sciatica in a mammal comprising administering to the mammal a therapeutically effective amount of an antibody that blocks TNF-.alpha. activity, wherein the antibody is selected from the group consisting of murine monoclonal antibodies, chimeric antibodies, humanized antibodies and human monoclonal antibodies. 19. The method of claim 18, wherein the antibody that blocks TNF-.alpha. activity is a complete or intact antibody. 20. The method of claim 16 or 18, wherein the antibody that blocks TNF-.alpha. activity is selected from the group consisting of infliximab, CDP-571, D2E7 and CDP-870. 21. The method of claim 16 or 18, wherein the antibody that blocks TNF-.alpha. activity comprises an immunogenic fragment of an antibody which binds to an epitope of TNF-.alpha.. 22. The method of claim 18, wherein the immunogenic fragment is selected from the group consisting of Fab fragments, scFv, and F(ab)2 fragments. 23. The method of claim 16 or 18, wherein the antibody is administered locally. 24. The method of claim 16 or 18, wherein the antibody is administered epidurally.

Details for Patent 8,057,792

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2018-09-25
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.